GlaxoSmithKline
This study is for adult participants with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who continue to experience exacerbations despite standard of care triple therapy treatment. It will assess the effectiveness and safety of two investigational drugs, GSK3862995B and GSK5784283, given together compared to a placebo in addition to standard of care.
Inclusion Criteria: * Participants must be greater than or equal to (\>=) 40 to less than or equal to (\<=) 80 years of age, at the time of signing the informed consent * Basal Metabolic Rate (BMI) \>= 16 kilogram per meter square (kg/m\^2) * Moderate to severe COPD with frequent exacerbations, defined as * a clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year prior to the screening visit; * a post-salbutamol FEV1/Forced vital capacity (FVC) ratio of less than (\<) 0.70 and a post-salbutamol FEV1 greater than…
Participants will receive GSK3862995B.
Participants will receive GSK5784283.
Participants will receive matching Placebo.